Treatment of elderly non-small cell lung cancer patients with three different schedules of weekly paclitaxel in combination with carboplatin

Subanalysis of a randomized trial

Suresh Ramalingam, John Barstis, Michael C. Perry, Renato V. La Rocca, Sreenivasa R. Nattam, David Rinaldi, Ray Clark, Glenn M. Mills, Chandra Belani

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

BACKGROUND: Administration of paclitaxel on a weekly schedule in combination with carboplatin is associated with a lower incidence of neuropathy and myelosuppression. The authors conducted subgroup analysis of their randomized phase II study of three different schedules of weekly paclitaxel with carboplatin to determine the efficacy of each regimen in elderly patients (aged ≥ 70 years) with advanced non-small-cell lung cancer (NSCLC). METHODS: Patients with advanced NSCLC were randomized to one of three different weekly paclitaxel/carboplatin regimens. After four cycles of chemotherapy, those with objective response or stable disease were randomized to weekly paclitaxel or observation as maintenance therapy. Four hundred three patients were enrolled in the study, of whom 111 (28%) were aged 70 years or older. RESULTS: The treatment regimen of weekly paclitaxel (100 mg/m for 3 of 4 weeks) and carboplatin (area under the curve = 6 mg/ml/min once every 4 weeks) (arm 1) was associated with the best therapeutic index overall. The median survival and 1-year survival rates were 11.3 months and 50% for patients in the ≥70 years cohort versus 11.2 months and 46% for the <70 years cohort in arm 1. Efficacy results were comparable between the two groups in the other arms as well. Grade 4 neutropenia and febrile neutropenia occurred in 13.6% and 2.3% in the ≥70 years cohort compared with 4.5% and 1.1% in the <70 years cohort in arm 1. CONCLUSION: The weekly regimen of paclitaxel administered in combination with carboplatin is tolerated well by elderly NSCLC patients and has comparable efficacy with younger patients.

Original languageEnglish (US)
Pages (from-to)240-244
Number of pages5
JournalJournal of Thoracic Oncology
Volume1
Issue number3
DOIs
StatePublished - Jan 1 2006

Fingerprint

Carboplatin
Paclitaxel
Non-Small Cell Lung Carcinoma
Appointments and Schedules
Therapeutics
Febrile Neutropenia
Neutropenia
Area Under Curve
Survival Rate
Observation
Drug Therapy
Survival
Incidence

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Ramalingam, Suresh ; Barstis, John ; Perry, Michael C. ; La Rocca, Renato V. ; Nattam, Sreenivasa R. ; Rinaldi, David ; Clark, Ray ; Mills, Glenn M. ; Belani, Chandra. / Treatment of elderly non-small cell lung cancer patients with three different schedules of weekly paclitaxel in combination with carboplatin : Subanalysis of a randomized trial. In: Journal of Thoracic Oncology. 2006 ; Vol. 1, No. 3. pp. 240-244.
@article{a63e5b1b01664f80885b7547c974e9d5,
title = "Treatment of elderly non-small cell lung cancer patients with three different schedules of weekly paclitaxel in combination with carboplatin: Subanalysis of a randomized trial",
abstract = "BACKGROUND: Administration of paclitaxel on a weekly schedule in combination with carboplatin is associated with a lower incidence of neuropathy and myelosuppression. The authors conducted subgroup analysis of their randomized phase II study of three different schedules of weekly paclitaxel with carboplatin to determine the efficacy of each regimen in elderly patients (aged ≥ 70 years) with advanced non-small-cell lung cancer (NSCLC). METHODS: Patients with advanced NSCLC were randomized to one of three different weekly paclitaxel/carboplatin regimens. After four cycles of chemotherapy, those with objective response or stable disease were randomized to weekly paclitaxel or observation as maintenance therapy. Four hundred three patients were enrolled in the study, of whom 111 (28{\%}) were aged 70 years or older. RESULTS: The treatment regimen of weekly paclitaxel (100 mg/m for 3 of 4 weeks) and carboplatin (area under the curve = 6 mg/ml/min once every 4 weeks) (arm 1) was associated with the best therapeutic index overall. The median survival and 1-year survival rates were 11.3 months and 50{\%} for patients in the ≥70 years cohort versus 11.2 months and 46{\%} for the <70 years cohort in arm 1. Efficacy results were comparable between the two groups in the other arms as well. Grade 4 neutropenia and febrile neutropenia occurred in 13.6{\%} and 2.3{\%} in the ≥70 years cohort compared with 4.5{\%} and 1.1{\%} in the <70 years cohort in arm 1. CONCLUSION: The weekly regimen of paclitaxel administered in combination with carboplatin is tolerated well by elderly NSCLC patients and has comparable efficacy with younger patients.",
author = "Suresh Ramalingam and John Barstis and Perry, {Michael C.} and {La Rocca}, {Renato V.} and Nattam, {Sreenivasa R.} and David Rinaldi and Ray Clark and Mills, {Glenn M.} and Chandra Belani",
year = "2006",
month = "1",
day = "1",
doi = "10.1016/S1556-0864(15)31574-4",
language = "English (US)",
volume = "1",
pages = "240--244",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "3",

}

Treatment of elderly non-small cell lung cancer patients with three different schedules of weekly paclitaxel in combination with carboplatin : Subanalysis of a randomized trial. / Ramalingam, Suresh; Barstis, John; Perry, Michael C.; La Rocca, Renato V.; Nattam, Sreenivasa R.; Rinaldi, David; Clark, Ray; Mills, Glenn M.; Belani, Chandra.

In: Journal of Thoracic Oncology, Vol. 1, No. 3, 01.01.2006, p. 240-244.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Treatment of elderly non-small cell lung cancer patients with three different schedules of weekly paclitaxel in combination with carboplatin

T2 - Subanalysis of a randomized trial

AU - Ramalingam, Suresh

AU - Barstis, John

AU - Perry, Michael C.

AU - La Rocca, Renato V.

AU - Nattam, Sreenivasa R.

AU - Rinaldi, David

AU - Clark, Ray

AU - Mills, Glenn M.

AU - Belani, Chandra

PY - 2006/1/1

Y1 - 2006/1/1

N2 - BACKGROUND: Administration of paclitaxel on a weekly schedule in combination with carboplatin is associated with a lower incidence of neuropathy and myelosuppression. The authors conducted subgroup analysis of their randomized phase II study of three different schedules of weekly paclitaxel with carboplatin to determine the efficacy of each regimen in elderly patients (aged ≥ 70 years) with advanced non-small-cell lung cancer (NSCLC). METHODS: Patients with advanced NSCLC were randomized to one of three different weekly paclitaxel/carboplatin regimens. After four cycles of chemotherapy, those with objective response or stable disease were randomized to weekly paclitaxel or observation as maintenance therapy. Four hundred three patients were enrolled in the study, of whom 111 (28%) were aged 70 years or older. RESULTS: The treatment regimen of weekly paclitaxel (100 mg/m for 3 of 4 weeks) and carboplatin (area under the curve = 6 mg/ml/min once every 4 weeks) (arm 1) was associated with the best therapeutic index overall. The median survival and 1-year survival rates were 11.3 months and 50% for patients in the ≥70 years cohort versus 11.2 months and 46% for the <70 years cohort in arm 1. Efficacy results were comparable between the two groups in the other arms as well. Grade 4 neutropenia and febrile neutropenia occurred in 13.6% and 2.3% in the ≥70 years cohort compared with 4.5% and 1.1% in the <70 years cohort in arm 1. CONCLUSION: The weekly regimen of paclitaxel administered in combination with carboplatin is tolerated well by elderly NSCLC patients and has comparable efficacy with younger patients.

AB - BACKGROUND: Administration of paclitaxel on a weekly schedule in combination with carboplatin is associated with a lower incidence of neuropathy and myelosuppression. The authors conducted subgroup analysis of their randomized phase II study of three different schedules of weekly paclitaxel with carboplatin to determine the efficacy of each regimen in elderly patients (aged ≥ 70 years) with advanced non-small-cell lung cancer (NSCLC). METHODS: Patients with advanced NSCLC were randomized to one of three different weekly paclitaxel/carboplatin regimens. After four cycles of chemotherapy, those with objective response or stable disease were randomized to weekly paclitaxel or observation as maintenance therapy. Four hundred three patients were enrolled in the study, of whom 111 (28%) were aged 70 years or older. RESULTS: The treatment regimen of weekly paclitaxel (100 mg/m for 3 of 4 weeks) and carboplatin (area under the curve = 6 mg/ml/min once every 4 weeks) (arm 1) was associated with the best therapeutic index overall. The median survival and 1-year survival rates were 11.3 months and 50% for patients in the ≥70 years cohort versus 11.2 months and 46% for the <70 years cohort in arm 1. Efficacy results were comparable between the two groups in the other arms as well. Grade 4 neutropenia and febrile neutropenia occurred in 13.6% and 2.3% in the ≥70 years cohort compared with 4.5% and 1.1% in the <70 years cohort in arm 1. CONCLUSION: The weekly regimen of paclitaxel administered in combination with carboplatin is tolerated well by elderly NSCLC patients and has comparable efficacy with younger patients.

UR - http://www.scopus.com/inward/record.url?scp=34247877781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247877781&partnerID=8YFLogxK

U2 - 10.1016/S1556-0864(15)31574-4

DO - 10.1016/S1556-0864(15)31574-4

M3 - Article

VL - 1

SP - 240

EP - 244

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 3

ER -